Nexavar Rival Offers Natco Opportunity To Build On Lenalidomide Launch
Viatris Launches First Sorafenib Generic As Teva-Partnered Revlimid Rival Lifts Natco In Q4
Executive Summary
Viatris and Natco have introduced the first US generic version of Nexavar, with the exclusive launch expected to further boost India’s Natco after a healthy financial fourth quarter that was bolstered by revenues from the firm’s recent launch of a Revlimid rival with Teva.
You may also be interested in...
Generics Bulletin Editor’s Picks For Q2 2022
Looking back over the second quarter of 2022, Generics Bulletin executive editor Dave Wallace picks out highlights from April to June that include multiple first generic and biosimilar launches, some noteworthy executive moves, further preparation for biosimilar competition to Humira in the US, and a major European industry conference.
Momenta Sues Viatris Over Copaxone Generic – Five Years After Launch
One Copaxone (glatiramer acetate) ANDA sponsor is suing another for alleged patent infringement, with Momenta filing a lawsuit against Viatris and its partners in a US district court.
Study Offers Support For Biosimilar-To-Biosimilar Switching
A new paper has examined the issue of biosimilar-to-biosimilar switching, concluding that it is a safe and effective clinical practice but highlighting a lack of current health authority regulations or guidance on the subject.